Shenaz Bagha on Muck Rack

Shenaz Bagha

Verified
As seen in: Healio, EIN News, Endocrine Today, Healio Allergy/Asthma, Healio Cardiology, Healio Gastroenterology, Healio Neurology, Healio Primary Care, HemOnc Today, Nephrology News & Issues, Healio Pulmonology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shenaz

Contact Shenaz, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

More than half of patients with tardive dyskinesia see symptom remission with valbenazine

|
By Richard Gawel Verified, Shenaz Bagha Verified, Dawn Vanderhoef
| Citeline Verified
Key takeaways: Patients took 40 mg or 80 mg of daily valbenazine for 48 weeks. The Abnormal Involuntary Movement Scale was used to measure improvement. Movement severity began receding toward baseline after ending treatment. More than half of patients with tardive dyskinesia who used valbenazine experienced symptomatic remission at 48 weeks, and nearly all of them had meaningful response, according to data presented at Psych Congress Elevate in Las Vegas.
Open in Who Shared View Duplicates (2) Issue with article?

More than half of patients with tardive dyskinesia see symptom remission with valbenazine

|
By Richard Gawel Verified, Shenaz Bagha Verified, Dawn Vanderhoef
| Citeline Verified
Key takeaways: Patients took 40 mg or 80 mg of daily valbenazine for 48 weeks. The Abnormal Involuntary Movement Scale was used to measure improvement. Movement severity began receding toward baseline after ending treatment. More than half of patients with tardive dyskinesia who used valbenazine experienced symptomatic remission at 48 weeks, and nearly all of them had meaningful response, according to data presented at Psych Congress Elevate in Las Vegas.
Open in Who Shared Issue with article?

Uptick in genetic testing expected to cause increased demand for services at ALS clinics

|
By Shawn Arrajj Verified, Shenaz Bagha Verified, Jennifer Morganroth
| Citeline Verified
Key takeaways: By 2035, the model projects more than 40 U.S. states will be seeing 50 or more additional visits per ALS clinic per year. The projected increase in demand can be tied to advances in genetic testing. Trends in the identification and treatment of ALS are expected to lead to a significant increase in clinic demand over the next decade, highlighting the need for greater investment, according to a study published in Neurology Genetics.
Open in Who Shared View Duplicates (3) Issue with article?
See all 3,369 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified